Generex Biotechnology (OTCMKTS:GNBT) Rating Increased to Hold at ValuEngine

Share on StockTwits

Generex Biotechnology (OTCMKTS:GNBT) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday, ValuEngine reports.

Shares of OTCMKTS GNBT opened at $1.12 on Thursday. The firm’s 50 day moving average price is $1.78 and its 200-day moving average price is $2.00. Generex Biotechnology has a 52-week low of $0.33 and a 52-week high of $1.64.

About Generex Biotechnology

Generex Biotechnology Corporation, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity.

Further Reading: What is diluted earnings per share (Diluted EPS)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Generex Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generex Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Pan American Silver  Stock Rating Upgraded by ValuEngine
Pan American Silver Stock Rating Upgraded by ValuEngine
SUMMIT THERAPEU/S  Rating Increased to Sell at ValuEngine
SUMMIT THERAPEU/S Rating Increased to Sell at ValuEngine
ValuEngine Upgrades Illumina  to Buy
ValuEngine Upgrades Illumina to Buy
ValuEngine Upgrades 1-800-Flowers.Com  to “Hold”
ValuEngine Upgrades 1-800-Flowers.Com to “Hold”
BRENNTAG AG/ADR  Downgraded by Deutsche Bank
BRENNTAG AG/ADR Downgraded by Deutsche Bank
Forward Air  Raised to Buy at Zacks Investment Research
Forward Air Raised to Buy at Zacks Investment Research


© 2006-2019 Ticker Report